drugset / Trial / NCT04988607
Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLC
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a prospective, multicenter, randomized, open label study to investigate the efficacy and safety of osimertinib plus bevacizumab versus osimertinib montherapy in treatment-naïve recurrent or metastatic NSCLC patients harbouring EGFR exon 21 L858R mutation.
Timeline
- Start
- 2021-08
- Primary completion
- 2024-11
- Completion
- 2025-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Comparator | Osimertinib | Small molecule | 80 mg | Oral |